Department of Orthopaedic Surgery, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.
Department of Orthopaedic Surgery, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.
Surgery. 2023 Oct;174(4):1041-1049. doi: 10.1016/j.surg.2023.06.013. Epub 2023 Jul 21.
Intertrochanteric fracture in the geriatric population is associated with poor prognosis, which may be attributed to consistent stress and the systemic inflammatory response. Dexamethasone is an exogenous glucocorticoid commonly used in clinical practice for broad anti-inflammatory action. The purpose is to investigate whether a single preoperative low-dose dexamethasone can improve the in-hospital prognosis in geriatric intertrochanteric fracture patients undergoing internal fixation surgery.
Between June 2020 and October 2022, 219 eligible patients with intertrochanteric fractures were in this study. After meeting the inclusion and exclusion criteria, 160 patients were randomly allocated to the dexamethasone or placebo groups (80 patients who are geriatric with an intertrochanteric fracture in each group). The patients in the dexamethasone group received 10 mg (2 mL) of dexamethasone intravenously, whereas the patients in the placebo group received 2 mL of saline intravenously within 30 minutes before being sent to the operating room. The efficacy-related outcomes (the first bed-chair transfer ability, in-hospital mortality, and length of stay) and safety-related outcomes (infection events and hyperglycemia) were collected for analysis.
There were no significant differences in the baseline characteristics between the 2 groups. The dexamethasone group had a significantly higher rate of the first bed-chair transfer than the placebo group (65.0% [52/80] vs 48.8% [39/80], relative risk = 1.46, 95% confidence interval = 1.02 to 2.11; P = .038). One patient in the dexamethasone group and 7 patients in the placebo group died during hospitalization (1.3% [1/80] vs 8.8% [7/80], relative risk = 0.92, 95% confidence interval = 0.86 to 0.99; P = .07). No differences were found in the length of stay, infections, and hyperglycemia between the 2 groups.
A single preoperative low-dose of dexamethasone can improve the in-hospital prognosis (increase the ability of the first bed-chair transfer and potentially decrease the in-hospital mortality) in geriatric intertrochanteric fracture patients after internal fixation surgery.
老年人股骨转子间骨折预后较差,这可能与持续的应激和全身炎症反应有关。地塞米松是一种临床常用的外源性糖皮质激素,具有广泛的抗炎作用。目的是探讨术前单次使用小剂量地塞米松是否能改善行内固定术的老年股骨转子间骨折患者的院内预后。
本研究纳入了 2020 年 6 月至 2022 年 10 月间符合纳入排除标准的 219 名股骨转子间骨折患者。经过筛选后,160 名患者被随机分配至地塞米松组或安慰剂组(每组各 80 名老年股骨转子间骨折患者)。地塞米松组患者在术前 30 分钟内静脉注射 10 mg(2 mL)地塞米松,而安慰剂组患者静脉注射 2 mL 生理盐水。收集两组患者的疗效相关结局(首次床椅转移能力、院内死亡率和住院时间)和安全性相关结局(感染事件和高血糖)进行分析。
两组患者的基线特征无显著差异。地塞米松组首次床椅转移能力显著高于安慰剂组(65.0% [52/80] vs 48.8% [39/80],相对风险=1.46,95%置信区间=1.02 至 2.11;P=0.038)。地塞米松组有 1 例患者和安慰剂组有 7 例患者在住院期间死亡(1.3% [1/80] vs 8.8% [7/80],相对风险=0.92,95%置信区间=0.86 至 0.99;P=0.07)。两组患者的住院时间、感染和高血糖发生率无差异。
术前单次使用小剂量地塞米松可改善行内固定术的老年股骨转子间骨折患者的院内预后(提高首次床椅转移能力,并可能降低院内死亡率)。